国药控股(01099)发布年度业绩,归母净利润71.55亿元 同比增加1.5% 末期股息每股0.69元

智通财经
12 hours ago

智通财经APP讯,国药控股(01099)发布截至2025年12月31日止年度业绩,该集团取得收入人民币5751.68亿元(单位下同),同比减少1.6%;母公司持有者应占溢利71.55亿元,同比增加1.5%;每股盈利2.29元,拟派发末期股息每股0.69元。

营运效率提升方面,本集团锚定规模效应和成本领先战略,推进费用压降和精益化管理。截至2025年末,本集团整体费用率同比下降0.25个百分点,有力抵消毛利额的下降影响。报告期内,经营性现金流实现净流入为141.38亿元,较上年同期多流入25.92亿元,现金流管理成效突出;应收账款增幅显著收窄,应收账款专项治理显效;资产负债率同比下降2.12个百分点。依托内部治理效能的提升,本集团有效抵御市场波动压力,实现经营溢利率同比增长0.02个百分点,整体业务展现出强劲的抗风险能力与发展韧性,为“十四五”圆满收官及“十五五”战略谋篇布局奠定了坚实基础。

2025年,本集团聚焦高质量发展的首要任务,科学研判各区域市场态势和竞争格局,积极拓展市场份额,以改革创新驱动提质增效。报告期内,三大主营业务板块延续差异化发展态势。其中,医药分销板块收入占比达到72.79% ,同比下降0.37个百分点;器械分销板块收入占比达到19.32% ,同比微降0.09个百分点;医药零售板块收入占比达到 6.42% ,同比上升0.50个百分点。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10